Echocardiographic integrated backscatter for assessing reduction of aortic valve calcifications by R-568 in a rat model of chronic kidney disease.
Chronic kidney disease (CKD) and secondary hyper-parathyroidism are associated with calcific aortic valve disease (CAVD). Innovative modalities for imaging CAVD are warranted. Our aim was to use echocardiographic calibrated integrated backscatter (cIB) to quantitatively determine the preventive effect of the calcimimetic R-568 on CAVD in a CKD rat model, and to compare the results with those of micro-computed tomography and histology. Thirty-six male Wistar rats were followed for 7 wk. Rats were divided into four groups with respect to treatment: (1) adenine 0.5% to induce CKD + vehicle; (2) adenine + R-568 (30 mg/kg/d); (3) control, normal diet + vehicle; (4) controls, normal diet + R-568. At week 7, cIB values of the aortic valve were significantly lower in R-568-treated group 2 than in vehicle-treated group 1. This was confirmed by the significantly lower calcified volume observed on micro-computed tomography and the calcified area observed on histology. There were no significant differences in fractional area change and aortic valve area between groups. In conclusion, echocardiographic cIB was able to quantitatively assess a reduction in CAVD by R-568 in a rat model of CKD.
Centrum Voor Hart- en Vaatziekten, UZ Brussel, Brussels, Belgium; In Vivo Cellular and Molecular Imaging, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium. Electronic address: broosens@vub.ac.be.
Bram
B
Roosens
Gezim
G
Bala
Steven
S
Droogmans
Jeroen
J
Hostens
Joan
J
Somja
Eléonore
E
Delvenne
Johan
J
Schiettecatte
Philippe
P
Delvenne
Vicky
V
Caveliers
Tony
T
Lahoutte
Guy
G
Van Camp
Bernard
B
Cosyns
D000814:Aniline Compounds; D000818:Animals; D001021:Aortic Valve / Q000000981:diagnostic imaging; D000082882:Bicuspid Aortic Valve Disease; D002114:Calcinosis / Q000000981:diagnostic imaging* / Q000209:etiology / Q000517:prevention & control*; D004452:Echocardiography / Q000379:methods*; D006330:Heart Defects, Congenital / Q000000981:diagnostic imaging* / Q000209:etiology / Q000517:prevention & control*; D006349:Heart Valve Diseases / Q000000981:diagnostic imaging* / Q000209:etiology / Q000517:prevention & control*; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D008297:Male; D010627:Phenethylamines; D011437:Propylamines; D051381:Rats; D017208:Rats, Wistar; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D015203:Reproducibility of Results; D012542:Scattering, Radiation; D012680:Sensitivity and Specificity; D018511:Systems Integration; D016896:Treatment Outcome
D000814:Aniline Compounds; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D010627:Phenethylamines; D011437:Propylamines
Aortic valve calcifications; Calcific aortic valve disease; Calcimimetic; Chronic kidney disease; Integrated backscatter; Secondary hyper-parathyroidism; Small animal